| content | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
Nadifloxacin
|
|
| Systematic (IUPAC) name | |
| 9-Fluoro-8-(4-hydroxy-piperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C19H21FN2O4 |
| Mol. mass | 360.379 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Nadifloxacin (INN, brand names Acuatim, Nadoxin, Nadixa) is a topical fluoroquinolone antibiotic for the treatment of acne vulgaris.[1]
It is also used to treat bacterial skin infections.
References
- ^ Murata K, Tokura Y (March 2007). "[Anti-microbial therapies for acne vulgaris: anti-inflammatory actions of anti-microbial drugs and their effectiveness]" (in Japanese). J. UOEH 29 (1): 63–71. PMID 17380730. Retrieved on 2008-05-27.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||
|
|||||||||||||||||||||||||||
